Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Medical Regulation topic
No spam. Unsubscribe anytime.
Lawmakers hear clash over bill to shield clinicians from disciplinary action for speech and off‑label care
Summary
A New Hampshire Health & Human Services committee heard competing testimony on HB 1117, which would limit disciplinary action against health‑care providers for certain recommendations or off‑label prescribing. Medical groups warned it would erode standards of care and licensing board authority; proponents framed it as preserving physician judgment and patient access.
A legislative committee heard hours of testimony on HB 1117, a bill backed by supporters as a measure to protect health‑care providers’ speech and clinical discretion and opposed by medical groups as an erosion of standards and regulatory authority.
Proponents including Robert Warybachop, reading testimony for Representative McGrath, argued the measure would protect physicians who offer emerging or off‑label treatments. Warybachop cited historical examples — tobacco advertising by doctors and contested pandemic treatments — to argue that commercial or institutional pressure can suppress dissenting medical voices and that physicians must retain latitude to recommend off‑label therapies in individualized care.
The New Hampshire Medical Society’s Mora Weston, however, told the committee the bill would “erode evidence‑based standards of care” and shield practitioners who recommend therapies outside current clinical standards. The society warned the proposal would limit the ability of licensing boards and other regulators to hold providers accountable and could encourage litigation through a private right of action included in the draft.
Representative Lucy Weber and other members also raised concerns that the statute would elevate a subjective “good‑faith” standard above clinical evidence and could conflict with existing state law and professional codes, noting specific statutory cross‑references discussed during questioning. Office of Professional Licensure and Certification testimony flagged drafting ambiguities about what constitutes prohibited discipline versus permissible due process and recommended that the bill be harmonized with existing appeals procedures.
Committee members pressed witnesses on constitutional implications after a recent Supreme Court decision cited by one questioner. Legal and policy questions about the bill’s scope — whether it protects speech only or also limits sanctions for clinical practice — were a recurring theme in the Q&A.
Several parents and rare‑disease advocates urged passage to ensure physicians could discuss options and offer off‑label approaches when no FDA‑approved therapy exists. Opponents emphasized patient safety, the role of professional boards, and the need for precise statutory language to avoid unintended consequences.
The committee did not take final action during the hearing; lawmakers indicated follow‑up drafting and clarification would be required before any vote.
